In compliance to Regulation 44 of SEBI (LODR) Regulations, 2015, as amended from time to time (Listing Regulations), please find enclosed herewith voting results of the 40th electroic Annual ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Gennex Laboratories held its 40th Annual General Meeting on September 30, 2025 via video conferencing, and all five resolutions were passed with overwhelming shareholder support. The resolutions included adoption of audited standalone and consolidated financial statements for FY ended March 31, 2025, re-appointment of Mr. Arihant Baid (DIN: 01171845) as Director liable to retire by rotation, regularization of Mr. Sandeep Kumar Daga (DIN: 00860908) as a Non-Executive and Non-Independent Director, appointment of Mr. Md. Tausif Shamim as Secretarial Auditor, and ratification of remuneration of Cost Auditors M/s. Sai Krishna & Associates for FY 2025-26. Out of 24.29 crore total shares outstanding, only about 3.12 crore shares (12.84%) were voted, with promoters voting 54.15% of their holdings in favor. Every resolution received over 99.99% votes in favor, with negligible dissent (just 697 to 847 votes against across all resolutions). The e-voting was conducted from September 27 to September 29, 2025, with the cut-off date being September 23, 2025.
The clean approval of all routine AGM resolutions indicates smooth corporate governance with no shareholder pushback on financials or director appointments. However, the relatively low public participation (~0.07% of public non-institutional shares voted) is typical for small-cap companies and unlikely to move the stock price.